You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growthSBC: ReveraGen BioPharma, Inc. Topic: NICHD
There is increasing interest in the use of biomarkers in clinical drug developmentwith much of thest Century Cures Act focused on encouraging this approachIdeallybiomarkers could provide and acute and objective read out of drug mechanism of actionpharmacodynamic biomarkersor prediction of later clinical benefit or harmsurrogate outcome measureHoweververy few biomarkers have been validated for rout ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
Production and Characterization of Human Immunoglobulin Producing Goats for Diagnostic Reagents and TherapeuticsSBC: SAB CAPRA, LLC Topic: NIAID
Project Summary A research plan is proposed to engineer goats that produce fully human immunoglobulinThese animals will be evaluated as a candidate platform system for production of both targeted therapeutic immunoglobulin as well as reagent antibodies for standards and controls of serological assays of human clinical samplesPrevious studies have demonstrated that ungulates such as cattle can prod ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
3D Holographic Guidance, Navigation, and Control (3D GN&C) for Endovascular Aortic Repair (EVAR)SBC: CENTERLINE BIOMEDICAL INC Topic: NHLBI
Project Summary This project will develop newD visualization to improve stent graft deployment during minimally invasive endovascular aortic repairEVARby overcoming limitations ofD x ray fluoroscopyfluoroD holographic guidancenavigation and controlD GNandamp Cwill be provided to decrease fluoro radiation dose burden to patients and OR staff during treatment of aortic aneurysmsparticularly when dep ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
Development and non-clinical GLP testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors.SBC: KIROMIC BIOPHARMA INC Topic: NHLBI
AtheroSclerotic CardioVascular DiseaseASCVDis caused by inflammation within arteriesWhite blood cells enter the arterial wallsmacrophages become engorged with lipid cholesterol and summon other inflammatory cells to form plaques which ultimately rupture or occlude the arterykilling down stream tissuee gheart attackASCVD remains a major cause of morbidity and mortality of the elderlyCoronary artery ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: COLUMBUS NANOWORKS, INC. Topic: 400
Fluorescent nanodiamonds are biocompatibleinfinitely photostableand fluoresce in a variety of wavelengthsincluding the near infraredNIRregionThese characteristics suggest transformative applications in areas ranging from pure biological research to biomedical imagingwhere protein conjugated nanodiamonds could be targeted to specific tissues in living patients or even structures within individual c ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: BERTEC CORP Topic: NIA
Falls are a significant source of early morbidity and mortality in the aging populationyet the neurologicalsensoryand motor changes that lead to increased fall risk often escape early identification and interventionVital signs are commonly used in clinical settings to assess the cardiovascular systemblood pressureheart rateimmune systembody temperatureand the respiratory systemrespiratory rateto e ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: TDA RESEARCH, INC. Topic: 102
Project Summary AbstractDevelopment of a Nerve Cuff Electrode from Soft and Elastomeric Conducting Wires STTR Phase I ApplicationPIBrady ClapsaddleTDA ResearchIncBio electronic interfaces are used in a wide array of applications for recording and providing electrical impulses to treat diseaseOne common interface device for the PNS is the cuff electrodeCurrent cuff electrodes have many failure mode ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: NEOGENE BIOSCIENCES, LLC Topic: NIA
DESCRIPTION (provided by applicant): The long term goal of this project is to develop and commercialize noninvasive equipment, called the sleep and respiratory track (SARTrak) system, for high throughput detection of sleep apnea in animals. The specific goal for the Phase I application is to design and evaluate a basic model of the SARTrak system with eight chambers (one chamber per animal), i.e. ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: TOMEGAVAX, INC. Topic: NIAID
DESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC Topic: NIAID
DESCRIPTION (provided by applicant): In the last decade, Acinetobacter baumannii has emerged as one of the most highly antibiotic-resistant pathogens in the United States (US) and throughout the world. These infections are increasingly prevalent and highlylethal, killing 50-60% of those infected. Worse, strains of A. baumannii that no known antibiotic will kill have now emerged, and will continue ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health